Corsair Pharma
Silver Spring
Maryland
United States
About Corsair Pharma
Corsair Pharma, Inc. is a development stage biotechnology company operating as a portfolio company of Velocity Pharmaceutical Development, LLC and is focused on the development of novel prodrugs of treprostinil to treat patients with PAH using a once-daily transdermal patch.
LEADERSHIP:
CEO: David Collier
5 articles about Corsair Pharma
-
Corsair Pharma Announces Appointment of George W. Mahaffey as Chief Executive Officer
12/11/2023
Corsair Pharma, Inc. today announced the appointment of George W. Mahaffey as Chief Executive Officer.
-
Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
9/20/2023
Corsair Pharma, Inc. today announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors.
-
Corsair Pharma, Inc. to Present at LifeSci Partners Annual Private Company Summer Symposium
7/15/2021
Corsair Pharma, Inc. today announced it will present at the LifeSci Partners Private Company Summer Symposium , to be held virtually July 21-23, 2021.
-
Corsair Pharma, Inc. to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension
6/24/2021
Corsair Pharma, Inc. today announced it will host a Key Opinion Leader (KOL) webinar to discuss the current treatment landscape for Pulmonary Arterial Hypertension (PAH) on Thursday, July 8 th , at 10:30 a.m. ET.
-
Corsair Pharma and United Therapeutics Enter Into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
1/3/2018
Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair's intellectual property for the development of treprostinil prodrug formulations.